Serum Institute of India, manufacturer of India’s most inoculated covid-19 vaccine Covishield will set up an early research centre for vaccines and biologicals in association with Symbiosis International University (SIU). The R&D (Research & Development) centre will lead the development of new vaccines, technologies, products and innovations in immunisation practices that provide equitable access to life-saving interventions, especially across Low- and Middle-Income Countries (LMICs). The entity will work towards improving health equity against future pandemics and infectious diseases.

“The research centre will be instrumental in advancing indigenous capabilities for end-to-end development of any futuristic technology and projects in the field of vaccines and biologics in collaboration with global partners,” Serum Institute CEO Adar Poonawalla said in a statement.

It will also ensure cross-programme coordination and collaboration, as the facility will be an ecosystem that would also have R&D centres for stem cells, nanotechnology, medical image analysis, applied artificial intelligence and waste resource management, among others.

Symbiosis International University’s faculty of health sciences dean Rajiv Yeravdekar said the initiative will help not only in addressing futuristic innovations but also needs of LMIC specific diseases.

Serum Institute of India is the world’s largest company in terms of COVID-19 vaccine production having manufactured over 500 million doses.

“We look forward to get the best available talent and equip them with the latest technology that facilitates global partnerships and collaborations. It will also abode a galaxy of scientists over the next 5-7 years and aim to be a front runner in building an equitable universal health framework,” he added.

News Summary:

• SII, Simbiosis will install a research center for vaccine development
• Check all news and articles from the latest Business news updates.